Oceanpine Capital
China's Oceanpine to go heavy on green-tech in Fund III
China-focused Oceanpine Capital plans to deploy over half of its third US dollar-denominated fund – which it is currently preparing to launch with a target of USD 600m – in green-tech investments.
China's Giant Biogene trades up after $70m Hong Kong IPO
Giant Biogene, a China-based producer of skin treatments that use bioactive ingredients, gained nearly 10% on debut following a HKD 549.4m (USD 70m) Hong Kong IPO.
China silicon supplier Lihao gets $305m Series B
Lihao Semiconductor, a China-based supplier of silicon materials used in solar panels, has raised CNY 2.2bn (USD 305m) in Series B funding from an investor group featuring Oceanpine Capital, V Fund, and Harvest Capital.
China EV battery maker raises $1.5b
Svolt Energy Technology, formerly the battery manufacturing unit of Chinese automaker Great Wall Motor, has raised RMB10.28 billion ($1.5 billion) in a Series B funding round led by Bank of China Investment.
China's Oceanpine raises $312m for renminbi hard-tech fund
Chinese technology and healthcare investor Oceanpine Capital has closed its Hardcore Technology Investment Fund on RMB2 billion ($312 million). LPs include government guidance funds and fund-of-funds in Suzhou, where the new vehicle is based.
China snack maker Weilong raises $549m, pursues HK IPO
China’s leading spicy snack food company Weilong has raised a $549 million pre-IPO round at a valuation of $9.4 billion and filed for a Hong Kong IPO.
Chinese COVID-19 vaccine developer Clover files for IPO
Clover Biopharmaceuticals, a Chinese pre-revenue drug developer that has raised $315 million across several funding rounds since 2011, has filed for a Hong Kong IPO.
VCs flock to Chinese chip designer Moore Threads
Moore Threads, a Chinese chip designer established as recently as last October by a team from Nvidia, has closed two funding rounds amounting to several billion renminbi.
China’s Clover Biopharmaceuticals gets $230m Series C
Chengdu-based Clover Biopharmaceuticals has raised $230 million in Series C funding led by GL Ventures and Temasek Holdings. Oceanpine Capital, OrbiMed, and Delos Capital all re-upped.
Fund focus: Oceanpine opens to external capital
Technology and healthcare-focused Oceanpine Capital sees the large GP commitment to its fund and the network of its founder as key differentiators in a competitive Chinese market
China's Oceanpine raises $400m for tech, healthcare deals
Chinese technology and healthcare investor Oceanpine Capital has completed its first external fundraise with $400 million in commitments.
Vision Fund leads $319m round for China's XtalPi
China and US-based artificial intelligence-enabled drug development platform XtalPi has raised $319 million in Series C funding led by SoftBank Vision Fund, the investment arm of insurer PICC Group, and Morningside Venture Capital.
China's Oceanpine reaches $200m first close on Fund II
Oceanpine Capital has reached a first close of $200 million on its second fund, 30% of which was committed by the GP. The target is $400 million.
Chinese investors lead round for US influenza specialist
Ansun BioPharma, a US-based drug developer led by a former executive at healthcare-focused VC firms Caduceus Asia Partners and OrbiMed, has raised $80 million in Series B funding from a predominantly Chinese investor base.
China's Up Fintech trades up after $104m US IPO
Up Fintech, an online brokerage firm focused on global Chinese investors that operates in Asia as Tiger Brokers, gained more than 36% in its first day of trading on NASDAQ after raising $104 million in its IPO.
China's Horizon Robotics hits $3b valuation with Series B
Horizon Robotics, a Chinese developer of microprocessors that support machine learning and artificial intelligence (AI) technologies, has raised $600 million in Series B funding at a valuation of $3 billion.
VC-backed Chinese online brokerage files for US listing
Chinese online brokerage Tiger Brokers, which is backed by smart phone maker Xiaomi and a number of venture capital firms, has filed for an IPO in the US.
Deal focus: Oceanpine sees value amidst traffic
Shansong has received $60 million in an initial tranche of Series D funding as it seeks to outgrow the competition in China's courier services market